Nusano (previously known as Alpha Source Inc./Alpha Isotopes) filed paperwork with the United States Securities and Exchange Commission on October 24, 2018 detailing a $41 million seed funding round from investors.
With its patented technology, Nusano is working to transform the production of medical-grade radioisotopes to enable advancements in cancer treatment and health care.
Read more in the Los Angeles Business Journal
From MedicalXpress: A team of researchers has developed a new method that suppresses the distribution of drugs to...
Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced that senior management will participate in the following investor conferences in October.
Nusano, Inc. has appointed pharmaceutical executive Alexandre Gibim as the company’s Chief Operations Officer (COO). Gibim will be responsible for enabling and scaling Nusano’s business functions to create a reliable domestic and global supply of medical radioisotopes, the active pharmaceutical ingredients (APIs) at the core of next-generation cancer therapeutics.
News from the United Kingdom's Institute of Cancer Research (ICR) published in The Lancet Oncology reports that...
With many now expecting radiopharamaceuticals to grow into a $20-30 billion market, investors are increasingly looking...
Nusano, Inc., a company working to stabilize and enable the production of cancer-fighting radioisotopes, is participating in two conferences in July 2023.
Sign up to receive company news and updates